📊 OBIO Key Takeaways
Is Orchestra BioMed Holdings, Inc. (OBIO) a Good Investment?
Orchestra BioMed is a pre-commercial stage medical device company burning $22.2M annually on $110K revenue, indicating severe unit economics and no clear path to profitability. While the company maintains adequate liquidity ($28.4M cash) with reasonable leverage (0.36x Debt/Equity), current burn rate depletes cash reserves in approximately 1.3 years without significant revenue acceleration or cost reduction.
OBIO shows extraordinary top-line growth but remains deeply unprofitable, with triple-digit negative operating and net margins and severely negative returns on capital. Liquidity is currently solid and leverage is low, but operating cash burn far outpaces cash on hand, implying a short runway and likely need for external financing. Until revenue quality proves durable and losses narrow materially, fundamentals skew unfavorable.
Orchestra BioMed Holdings, Inc. Key Strengths (OBIO)
- Strong liquidity position with 7.03x current ratio and $28.4M cash
- Controlled debt levels at 0.36x Debt/Equity ratio limiting financial distress risk
- Extreme revenue growth of 1169% YoY suggests early commercialization traction, though from minimal base
- Strong liquidity with very high current and quick ratios
- Low leverage (D/E 0.28x) and minimal capex needs
- Significant YoY revenue growth providing potential scale platform
OBIO Stock Risks: Orchestra BioMed Holdings, Inc. Investment Risks
- Severe cash burn of $22.2M annually against $110K revenue demonstrates unsustainable unit economics
- Negative operating margin of -20069% and negative free cash flow indicates company is pre-profitability with no visibility to breakeven
- Limited cash runway of approximately 1.3 years at current burn rate without achieving significant revenue growth or cost controls
- Missing gross profit data suggests potential product or operational reporting issues
- Persistent, large operating and net losses with highly negative margins
- Heavy cash burn versus cash balance, implying financing/dilution risk
- Revenue sustainability concerns given spike and lack of gross margin clarity
Key Metrics to Watch
- Quarterly revenue growth trajectory and achievement of $1M+ quarterly revenue milestone
- Operating cash burn rate and path to cash flow breakeven
- Gross margin visibility and achievement of positive contribution margins by product
- Operating cash flow (quarterly)
- Cash & equivalents (runway months)
Orchestra BioMed Holdings, Inc. (OBIO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.03x current ratio provides a solid financial cushion.
OBIO Profit Margin, ROE & Profitability Analysis
OBIO vs Healthcare Sector: How Orchestra BioMed Holdings, Inc. Compares
How Orchestra BioMed Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Orchestra BioMed Holdings, Inc. Stock Overvalued? OBIO Valuation Analysis 2026
Based on fundamental analysis, Orchestra BioMed Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Orchestra BioMed Holdings, Inc. Balance Sheet: OBIO Debt, Cash & Liquidity
OBIO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Orchestra BioMed Holdings, Inc.'s revenue has grown significantly by 848% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.66 indicates the company is currently unprofitable.
OBIO Revenue Growth, EPS Growth & YoY Performance
OBIO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $110.0K | -$18.8M | $-0.33 |
| Q3 2025 | $861.0K | -$13.5M | $-0.40 |
| Q2 2025 | $778.0K | -$13.5M | $-0.45 |
| Q1 2025 | $620.0K | -$13.5M | $-0.38 |
| Q3 2024 | $419.0K | -$10.9M | $-0.38 |
| Q2 2024 | $778.0K | -$10.9M | $-0.35 |
| Q1 2024 | $620.0K | -$10.9M | $-0.38 |
| Q3 2023 | $419.0K | -$5.7M | $-0.38 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Orchestra BioMed Holdings, Inc. Dividends, Buybacks & Capital Allocation
OBIO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Orchestra BioMed Holdings, Inc. (CIK: 0001814114)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OBIO
What is the AI rating for OBIO?
Orchestra BioMed Holdings, Inc. (OBIO) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are OBIO's key strengths?
Claude: Strong liquidity position with 7.03x current ratio and $28.4M cash. Controlled debt levels at 0.36x Debt/Equity ratio limiting financial distress risk. ChatGPT: Strong liquidity with very high current and quick ratios. Low leverage (D/E 0.28x) and minimal capex needs.
What are the risks of investing in OBIO?
Claude: Severe cash burn of $22.2M annually against $110K revenue demonstrates unsustainable unit economics. Negative operating margin of -20069% and negative free cash flow indicates company is pre-profitability with no visibility to breakeven. ChatGPT: Persistent, large operating and net losses with highly negative margins. Heavy cash burn versus cash balance, implying financing/dilution risk.
What is OBIO's revenue and growth?
Orchestra BioMed Holdings, Inc. reported revenue of $110.0K.
Does OBIO pay dividends?
Orchestra BioMed Holdings, Inc. does not currently pay dividends.
Where can I find OBIO SEC filings?
Official SEC filings for Orchestra BioMed Holdings, Inc. (CIK: 0001814114) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OBIO's EPS?
Orchestra BioMed Holdings, Inc. has a diluted EPS of $-0.33.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is OBIO's fundamental grade?
Based on our AI fundamental analysis in June 2026, Orchestra BioMed Holdings, Inc. has a C grade with 74% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is OBIO stock overvalued or undervalued?
Valuation metrics for OBIO: ROE of -50.2% (sector avg: 15%), net margin of -18,810.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is OBIO's AI grade for 2026?
Our dual AI analysis gives Orchestra BioMed Holdings, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OBIO's free cash flow?
Orchestra BioMed Holdings, Inc.'s operating cash flow is $-22.2M, with capital expenditures of $184.0K. FCF margin is -20,320.0%.
How does OBIO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -18,810.0% (avg: 12%), ROE -50.2% (avg: 15%), current ratio 7.03 (avg: 2).